Glycolytic Enzymes as Vaccines Against Schistosomiasis: Testing Schistosoma mansoni Phosphoglycerate Mutase in Mice
Journal of Parasitology · 11.03.2024 · 110 (2) · 96-105
DOI: 10.1645/23-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Parasitology, erschienen am 11.03.2024. Verfasst von David B Pirovich und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Helminthology Laboratory, Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, Nor…. Hauptthemen laut MEDLINE: Schistosomiasis mansoni, Schistosomiasis, Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Schistosomiasis is a globally burdensome parasitic disease caused by flatworms (blood flukes) in the genus Schistosoma. The current standard treatment for schistosomiasis is the drug praziquantel, but there is an urgent need to advance novel interventions such as vaccines. Several glycolytic enzymes have been evaluated as vaccine targets for schistosomiasis, and data from these studies are reviewed here. Although these parasites are canonically considered to be intracellular, proteomic analysis has revealed that many schistosome glycolytic enzymes are additionally found at the host-interactive surface. We have recently found that the intravascular stage of Schistosoma mansoni (Sm) expresses the glycolytic enzyme phosphoglycerate mutase (PGM) on the tegumental surface. Live parasites display PGM activity, and suppression of PGM gene expression by RNA interference diminishes surface enzyme activity. Recombinant SmPGM (rSmPGM) can cleave its glycolytic substrate, 3-phosphoglycerate and can both bind to plasminogen and promote its conversion to an active form (plasmin) in vitro, suggesting a moonlighting role for this enzyme in regulating thrombosis in vivo. We found that antibodies in sera from chronically infected mice recognize rSmPGM. We also tested the protective efficacy of rSmPGM as a vaccine in the murine model. Although immunization generates high titers of anti-SmPGM antibodies (against both recombinant and native SmPGM), no significant differences in worm numbers were found between vaccinated and control animals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Helminthology Laboratory, Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, North Grafton, Massachusetts 01536.
ORCID-Profile: Patrick J Skelly
Förderung
- NIAID NIH HHS
Zitieren
APA
Pirovich, D. B., Da'dara, A. A., & Skelly, P. J. (2024). Glycolytic Enzymes as Vaccines Against Schistosomiasis: Testing Schistosoma mansoni Phosphoglycerate Mutase in Mice. Journal of Parasitology, 110(2), 96-105. https://doi.org/10.1645/23-7
Vancouver
Pirovich DB, Da'dara AA, Skelly PJ. Glycolytic Enzymes as Vaccines Against Schistosomiasis: Testing Schistosoma mansoni Phosphoglycerate Mutase in Mice. Journal of Parasitology. 2024;110(2):96-105. doi:10.1645/23-7
BibTeX
@article{Pirovich2024,
author = {Pirovich, David B and Da'dara, Akram A and Skelly, Patrick J},
title = {Glycolytic Enzymes as Vaccines Against Schistosomiasis: Testing Schistosoma mansoni Phosphoglycerate Mutase in Mice},
journal = {Journal of Parasitology},
year = {2024},
volume = {110},
number = {2},
pages = {96--105},
doi = {10.1645/23-7}
}
EUVIMED